



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Compounded Drug Products

Page: 1 of 3

Effective Date: 12/5/2025

Last Review Date: 11/18/2025

Applies to:  Maryland

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for compounded drug products under the patient's prescription drug benefit.

### Description:

N/A

### Applicable Drug List:

N/A

### Policy/Guideline:

**Compounded drug products will be covered with prior authorization when the following criteria are met:**

- The request is for any of the following: A) intravenous (IV) injection or infusion, B) anti-infective for injectable use (e.g., antibacterials, antivirals, antifungals), C) total parenteral nutrition (TPN), D) pyrimethamine, E) sirolimus for tuberous sclerosis where other dermatological treatments (e.g., laser therapy, surgery, dermabrasion) are inappropriate

**OR**

- The request is for tacrolimus (Prograf) or everolimus (Zortress) for a patient receiving a transplant

**OR**

- Each of the active ingredients in the compound are FDA-approved drugs

**AND**

- Each of the active ingredients in the compound are FDA-approved for the indication for which the compound is being prescribed

**AND**

- The compound route of administration (ROA) is the same as the FDA-approved route of administration for each active ingredient

**AND**

- The dosage or concentration of each active ingredient in the compound is equal to or below the FDA-approved dosage or concentration

**AND**

- The compound is not intended for anti-aging or cosmetic use, or is not a compound kit, or does not contain a bulk powder or dietary supplement

**AND**

- The request is not for a hormone therapy compound for menopause or for androgen decline due to aging, (e.g., testosterone, estrogen, progestin, bioidentical hormone)

**AND**

- The request is not for a gender-affirming care or fertility preservation related diagnosis

**AND**



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Compounded Drug Products

Page: 2 of 3

Effective Date: 12/5/2025

Last Review Date: 11/18/2025

Applies to:  Maryland

- Coverage is provided for additional fills of the compounded drug if the patient needs more than 1 fill per month (necessity may include continuation of antibiotic therapy, stability is less than a month, dose adjustment)  
**AND**
  - There is a current supply shortage of the commercially manufactured product  
**OR**
  - The patient has a medical need for a dosage form or dosage strength that is not available commercially or manufactured  
**OR**
  - The patient had an intolerance or contraindication to the commercially manufactured product (e.g., allergen or adverse effects due to inactive ingredients)  
**OR**

The commercial product has been discontinued by the pharmaceutical manufacturer for reasons other than lack of safety or effectiveness

#### Approval Duration and Quantity Restrictions:

##### Approval:

- Tacrolimus or everolimus for transplant: 36 months for members 12 years of age or older; until age 12 years of age for those under 12 years of age
- 6 months for all other approvals

**Quantity Level Limit:** Reference Formulary for drug specific quantity level limits

#### References:

1. 21 USC 353a: Pharmacy compounding From Title 21-FOOD AND DRUGS CHAPTER 9-FEDERAL FOOD, DRUG, AND COSMETIC ACT SUBCHAPTER V-DRUGS AND DEVICES Part A-Drugs and Devices. Available at: <https://uscode.house.gov/view.xhtml?hl=false&edition=prelim&req=granuleid%3AUUSC-prelim-title21-section353a&num=0&saved=%7CKGNvbXBvdW5kIGRydWdzKQ%3D%3D%7CdHJIZXNvcnQ%3D%7CdHJlZQ%3D%3D%7C15%7Ctrue%7Cprelim>. Accessed August 2025.
2. Compounding Quality Act. U.S. Food and Drug Administration. Pharmacy Compounding. Available at: <https://www.govinfo.gov/app/details/BILLS-113hr3204enr>. Accessed August 2025.
3. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act>. Accessed August 2025.
4. Human Drug Compounding. Available at: <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding>. Accessed August 2025.
5. Compounding and the FDA: Questions and Answers. Available at: <https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>. Accessed August 2025.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name:	Compounded Drug Products	Page:	3 of 3
Effective Date:	12/5/2025	Last Review Date:	11/18/2025
Applies to:	<input checked="" type="checkbox"/> Maryland		

6. USP Compounding Standards. Available at: <https://www.usp.org/compounding>. Accessed August 2025.
7. USP Compounding Standards and Beyond-Use Dates (BUDs). Available at: <https://www.usp.org/sites/default/files/usp/document/our-work/compounding/usp-bud-factsheet.pdf>. Accessed August 2025.
8. USP-NF Chapters on Pharmacy Compounding, 795. [https://www.uspnf.com/sites/default/files/usp\\_pdf/EN/USPNF/revisions/gc795.pdf](https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/gc795.pdf). Accessed August 2025.
9. Is it Really FDA Approved? Available at: <https://www.fda.gov/forconsumers/consumerupdates/ucm047470.htm>. Accessed August 2025.
10. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due>. Accessed August 2025.
11. Menopause. Available at: <https://www.fda.gov/consumers/womens-health-topics/menopause>. Accessed August 2025.
12. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy, Jackson L.M., Parker R.M., & Mattison D.R. (Eds.). (2020) *The clinical utility of compounded bioidentical hormone therapy: A review of safety, effectiveness, and use*. National Academies Press (US).
13. Drug Information (Drugs@FDA). Available at: <http://www.fda.gov/Drugs/default.htm>. Accessed August 2025.
14. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com> Accessed August 2025.
15. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> ([cited: 08/2025](#)).
16. Tuberous Sclerosis. Available at: <https://rarediseases.info.nih.gov/diseases/7830/tuberous-sclerosis>. Accessed August 2025.
17. Drug Nomenclature Monographs. Route of Administration. Available at: <https://www.fda.gov/drugs/data-standards-manual-monographs/route-administration>. Accessed August 2025.